加用别嘌醇调节硫嘌呤代谢以优化炎症性肠病治疗
本文综述了加用小剂量别嘌醇调节硫嘌呤代谢以优化炎症性肠病治疗的文献。病例系列、队列研究和一项随机试验表明,该策略可显著升高6-硫鸟嘌呤核苷酸水平并降低6-甲基巯基嘌呤水平,部分患者症状改善,不良反应和停药率相似或改善。加用别嘌醇可能适用于6-硫鸟嘌呤核苷酸水平低的特定患者,但需密切监测以防中性粒细胞减少等不良反应。
要点
- 加用别嘌醇可显著升高6-硫鸟嘌呤核苷酸水平并降低6-甲基巯基嘌呤水平。
- 部分患者症状改善或缓解,不良反应和停药率相似或改善。
- 适用于6-硫鸟嘌呤核苷酸水平低的特定患者,需密切监测中性粒细胞减少等。
核心结论
- 加用别嘌醇可能是优化特定低6-硫鸟嘌呤核苷酸水平炎症性肠病患者硫嘌呤代谢的选择。
- 适当护理和监测是必要的,以防止中性粒细胞减少或其他不良反应。
研究设计与样本
- 通过检索MEDLINE和Embase数据库获取基础与临床研究报道,由作者提取、审阅并评估相关文献。
- 纳入的研究包括病例系列、队列研究和一项随机试验,多数报告主要检测患者代谢物水平。
主要发现
- 文献普遍提示该策略成功显著升高6-硫鸟嘌呤核苷酸水平并降低6-甲基巯基嘌呤水平。
- 若干小样本报告提示6-硫鸟嘌呤核苷酸水平升高的患者症状改善或症状缓解。
- 服用硫嘌呤并开始别嘌醇的患者中,不良反应和停药率保持相似或改善。
临床怎么用
- 对于6-硫鸟嘌呤核苷酸水平低的特定炎症性肠病患者,可考虑加用别嘌醇以优化硫嘌呤代谢。
- 加用别嘌醇期间必须进行适当护理和监测,以预防中性粒细胞减少或其他不良反应。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Thiopurine drugs, including azathioprine and 6-mercaptopurine, are used commonly in patients with inflammatory bowel disease for maintenance of remission. Although generally well tolerated, adverse effects lead to discontinuation in a significant minority of patients. Pharmacogenomic studies have suggested that metabolic breakdown of azathioprine in an individual is genetically determined. Coupled with the fact that certain thiopurine metabolites, notably 6-thioguanine nucleotide and 6-methylmercaptopurine, are associated with antiinflammatory effects and adverse effects, respectively, some investigators have examined intentionally shunting the metabolism of azathioprine toward increasing 6-thioguanine nucleotide levels by using low doses of the xanthine oxidoreductase inhibitor allopurinol to improve efficacy and decrease toxicity of azathioprine in patients with inflammatory bowel disease. We performed a search of the MEDLINE and Embase databases for basic and clinical research reports of this modality. Pertinent articles were retrieved, reviewed, and assessed by the authors. Case series, cohort studies, and one randomized trial have investigated adding allopurinol to azathioprine therapy in patients with inflammatory bowel disease. Most reports primarily examined metabolite levels in these patients. In general, the literature suggests that this modality was successful at significantly increasing 6-thioguanine nucleotide levels while decreasing 6-methylmercaptopurine levels. Several small reports have suggested that patients with increased 6-thioguanine nucleotide levels had improved symptoms or symptom remission. Adverse effects and discontinuation rates remained similar or were improved in patients who were taking a thiopurine and started allopurinol. In conclusion, the addition of allopurinol may be an option for optimizing thiopurine metabolite production in select patients with low 6-thioguanine nucleotide levels. Appropriate care and monitoring of these patients are mandatory to prevent neutropenia or other adverse effects.
引用
- Wall GC, Muktar H, Effken C, et al. Addition of Allopurinol for Altering Thiopurine Metabolism to Optimize Therapy in Patients with Inflammatory Bowel Disease. Pharmacotherapy. 2018. PMID: 29197117. doi:10.1002/phar.2067
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。